Let's Talk About CKD

Let's Talk about CKD

Chronic kidney disease (CKD) is a common1 yet widely underrecognized and potentially deadly condition2,3 and is estimated to affect more than 160 million people with type 2 diabetes (T2D) worldwide.4,5,6 CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced.7,8

 

Regular testing for the earliest signs of kidney disease is essential to slow progression, and early referral of CKD patients has been shown to improve outcomes.9 The KDIGO, ADA, and EASD guidelines recommend testing both eGFR and UACR at least once a year in patients with CKD and T2D.9,10,11

 

Hear from leading experts below on how outcomes can be improved for patients living with CKD and T2D, alongside insights from their experience and best practices.

 

Professor Peter Rossing

Diabetologist
Professor Peter Rossing

Head of Complications Research at Steno Diabetes Center Copenhagen, Denmark

Carolyn Lam

Cardiologist
Professor Carolyn Lam

Senior Consultant of the National Heart Centre, Singapore

Richard Hobbs

Primary Care Physician
Professor Richard Hobbs

Nuffield Professor of Primary Care Health Sciences, UK

Christoph Wanner

Nephrologist
Professor Christoph Wanner

Professor of Medicine and Head of the Division of Nephrology University Hospital of Würzburg, Germany

THE SILENT NATURE OF CKD IN T2D

With CKD in T2D being the leading cause of end-stage kidney disease12, more needs to be done to support these patients. Watch the video below to learn more about the silent nature of CKD in T2D.

 

The Silent Nature of CKD in T2D

YYMMDD Author/Uploaded by
Early Detection & Intervention in CKD and T2D

Early Detection & Intervention in CKD and T2D
 

The panel discusses the type of tests and the testing protocols that are involved in diagnosing CKD early.

Increased Cardiovascular Risk in Patients with CKD and T2D

Increased Cardiovascular Risk in Patients with CKD and T2D
 

Professor Carolyn Lam (Senior Consultant of the National Heart Centre, Singapore) and Professor Richard Hobbs (Nuffield Professor of Primary Care Health Sciences,UK) discuss the close link between CKD and T2D.

The Need for a Collaborative Multidisciplinary Approach
 in CKD in T2D

The Need for a Collaborative Multidisciplinary Approach in CKD in T2D

The panel discusses what comprises a collaborative approach for patients with CKD in T2D that need multidisciplinary care.

Patient Education in CKD in T2D

Patient Education in CKD in T2D

 

The panel discusses the key challenges when clinicians discuss kidney health with patients with CKD and T2D.

The Role of Healthcare Providers Beyond the Specialists

The Role of Healthcare Providers Beyond the Specialists
 

The panel discusses the different roles of health care providers to support the management of patients with CKD and T2D as a broader team.

Sign up below for updates on CKD and T2D, and news from Bayer.
SIGN UP FOR UPDATES

References:

  • NHS.UK. Chronic kidney disease. Available at: https://www.nhs.uk/conditions/kidney-disease/. 2019. [Last Accessed: April 2022]. Return to content
  • Breyer MD et al. Developing Treatments for Chronic Kidney Disease in the 21st Century. Seminars in Nephrology. 2016. 36(6), 436–447. Return to content
  • National Kidney Foundation. 2021. Chronic Kidney Disease Goes Undetected in Those Most at Risk. Available at: https://www.kidney.org/news/newsroom/nr/CKD-Goes-Undetected-in-Those-Most-at-Risk. Last Accessed: April 2022. Return to content
  • Zheng Y, et al. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018. 14(2), 88-98. Return to content
  • Wu B, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Research and Care. 2016. 4(1), e000154. Return to content
  • International Diabetes Federation. IDF Diabetes Atlas, 9th ed. Brussels, Belgium; 2019. Return to content
  • Khan et al. Prevalence of Chronic Kidney Disease in Asia: A Systematic Review of Population-Based StudiesJ Coll Physicians Surg Pak. 2018. 28(12):960-966. Return to content
  • Zhong J, et al. A perspective on chronic kidney disease progression. American Journal of Physiology-Renal Physiology. 2017. 312(3), F375-F384. Return to content
  • KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2013. 3, 1-150. Return to content
  • American Diabetes Association Professional Practice Committee. Chronic kidney disease and risk management: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022. 45(Suppl.1): S175–S184. Return to content
  • Cosentino, Francesco et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European heart journal. 2020. vol. 41,2. 255-323. Return to content
  • Doshi S M, et al. Diagnosis and Management of Type 2 Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology. 2017. 12(8), 1366-1373. Return to content

Follow:

© 2022 Bayer AG

Last updated in June 2022

This website is intended to provide information to an international audience of healthcare professionals outside the USA and UK.

  • PP-KER-ALL-0067-1
Alt tag Alt tag